1792P Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAi elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors

Abstract

Targeting the bromodomain and extra-terminal motif (BET) protein BRD4 is an attractive target for cancer immunotherapy, as it exerts impacts on both cancer cells and T cells. Preclinical data suggests added therapeutic potential in co-targeting the immune checkpoint PD-1. INTASYL™ is a self-delivering RNAi platform that provides both highly efficient delivery to target cells without need for specialized drug delivery systems and strong gene silencing of multiple targets in a single drug formulation.